Could improving sleep boost a soldier’s recovery from post-traumatic stress disorder?

New York drug maker Tonix Pharma seems to think so; it’s testing a long-approved muscle relaxant, cyclopenzaprine, as a way to help calm the brain before sleep to subdue PTSD symptoms. The company just got breakthrough designation from the Food and Drug Administration, and will be entering Phase 3 trials in patients with military-related PTSD in the first quarter of 2017.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • The approval of cyclobenzaprine as a “breakthrough” simply shows how far we have to go in developing more meaningful pharmacologic treatments for PTSD.

  • Wonder what it will cost, considering cyclobenzaprine (Flexiril) costs about 11 cents a pill. Any studies showing the sublingual form is any better? PS: Amitriptyline and nortriptylline have similar chemical structures.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy